Protea Fund
Navera High Equity Strategy GBP

Quarterly Update - Q3 2026
30 September 2026



navera
INVESTMENT MANAGEMENT

Protea Fund – Navera High Equity Strategy GBP

Performance

	Q3 2026	YTD	2025	2024	2023	Last 5 years	Since 31 Jan 2019[1]
Protea Fund - Navera HE Strategy (Acc)[2]	**2.2%**	**-1.4%**	**-6.1%**	**11.6%**	**14.8%**	**17.6%**	**77.1%**
UK CPI +4%[3]	2.0%	5.8%	7.3%	6.6%	7.9%	49.8%	70.6%
UK CPI [3]	1.0%	2.8%	3.3%	2.6%	3.9%	28.1%	35.5%
Peer Group [4]	1.5%	9.2%	10.1%	9.3%	8.3%	29.9%	70.5%
MSCI AC World Equity Index (£)[5]	1.5%	14.4%	13.9%	19.6%	15.3%	75.5%	159.5%
FTSE All-Share Index (£)[5]	2.4%	9.8%	24.0%	9.5%	7.9%	68.2%	97.1%
Inv. Grade Corporate Bonds (1-10Y)[5]	-1.2%	0.1%	7.3%	4.4%	9.2%	6.6%	18.1%

Investment Mandate


Objective To protect our clients' assets and grow them significantly above inflation over the long-term

Risk Profile Medium/high risk with a strategic asset allocation range of 80-100% in equities

Equity sectors[6]

	% Weight	Names
Industrials	20.4%	AMETEK, Automatic Data Processing, Bunzl, Experian, HEICO, Hubbell Incorporated, RELX, Rollins, Schneider Electric, Verisk Analytics, Xylem
Information Technology	17.0%	Amphenol, Cadence Design Systems, Fabrinet, Keyence Corp, Microsoft, Taiwan Semiconductor Manufacturing Co
Health Care	13.7%	AbbVie, Boston Scientific, Intuitive Surgical, Labcorp Holdings, Roche, Thermo Fisher Scientific
Financials	10.5%	Hong Kong Exchanges & Clearing, London Stock Exchange Group, Marsh & McLennan, Mastercard
Consumer Discretionary	10.3%	Amazon, Compass Group, Next, Tractor Supply
Communication Services	3.2%	Alphabet
Materials	3.1%	Avery Dennison, Franco-Nevada
Consumer Staples	2.1%	Kerry

Asset Allocation (% of Portfolio)



Morningstar ESG Risk Rating™



High
5 out of 5 globes

Out of 8,979 Aggressive Allocation funds as at 30 September 2026. Based on 99% of eligible corporate AUM and long positions only. Sustainalytics provides company-level analysis used in the calculation of Morningstar's Historical ESG Risk Score.

Fund Performance figures are in Sterling, total returns with net dividends reinvested. [1]Performance since month of inception. [2]Protea Fund returns are net of all fees and costs. [3]UK CPI are the most recent figures at the time of publication and obtained from external sources. UK CPI +4% figures are calculated internally using methodology that may differ from external counterparties. [4]The ARC £ Equity Risk Index initial estimates are subject to revision. [5]All Indices are gross of fees. Where shown Inv. Grade Corporate Bonds (1-10Y) refers to BofA ML index. [6]Global Industry Classification Standard (GICS®), as determined by MSCI Inc. and S&P Global Market Intelligence, is used for sector classification of the securities and is shown only for comparability purposes. Source: Pictet, Bloomberg, Factset. All figures are unaudited and subject to change. Totals may not add precisely due to rounding.

Quarterly Update

Investment commentary

The fund rose by 2.2%. Several major themes that we are positioned for played out further during the quarter, enabling the fund to deliver solid performance despite difficult market conditions.

Our clients are looking to us to grow their wealth ahead of inflation. The fund has multiple engines for delivering inflation-beating growth in very different – and potentially challenging – environments. We are positioned for uncertainty, seeing huge embedded potential for growth in the fund, whilst also being prepared for the 'what ifs' through careful portfolio construction and our valuation discipline.

We were pleased to see the fund holding up well during market 'down days', as well as participating in up days. Meanwhile, under the hood, our companies continue to deliver operationally, with expected earnings growth of around 20% in 2026 (following 15% in 2025), and further double-digit growth expected in 2027. Our bond holdings have also been instrumental in navigating our way through this year, providing a positive contribution to performance in a period when most bond markets have lost money.

Today's equity market is 'k-shaped': a small group of stocks is being bid higher while many high-quality companies are increasingly on sale. This is typical investor behaviour in periods of market euphoria: we have been here before and at such times it pays to tread carefully. We see opportunity, and with some excellent companies trading at 20% or more off their share price peaks, we have been buying selectively (see **Transactions**).

A theme we've discussed previously – the rising cost of capital – passed an important milestone this quarter with US and UK bond yields rising to levels not seen since the early 2000s. This will put further pressure on many companies' ability to grow; Oracle's debt is now rated at one notch above junk bonds! We also saw more questions around the profitability of AI and a collective warning from AI's key creators about its potential risks. Together, these may prove to be a watershed between speculation and reality in which markets will increasingly value strong balance sheets, cash flow and good visibility of earnings underpinned by sound business fundamentals.

Given the climate of uncertainty, you might wonder why you're in the stock market at all. Our portfolio of equities is not the stock market. Rather, it is 35 carefully chosen businesses that work together as a portfolio to deliver durable, inflation-beating returns for you over the years ahead. We are doing something very different to the market: bringing together multiple sources of growth in a portfolio which, with a free cash flow yield almost 24% higher than the global equity market's, has rarely been cheaper during the past 10 years.

Performance

Leaders

+ Thermo Fisher Scientific (Thermo) is the world's Amazon of lab supplies. As such, it is positively exposed to growing R&D budgets in healthcare, materials science and technology. Almost 85% of Thermo's revenues come from recurring services and consumables. The application of AI to drug development is driving demand for hi-tech research tools to provide data for AI models. Thermo has been a first mover in AI integration and is collaborating with Nvidia to launch new equipment this year for autonomous labs.

+ Microsoft powered ahead this quarter after a strong earnings report in which revenue, growth and earnings per share all exceeded expectations. Investors particularly welcomed accelerating growth in its cloud business and progress in embedding AI in its core applications – such as Microsoft 365 Copilot topping 30 million paid seats. Amid current debates over AI and data security, Microsoft is positioning itself to be a preferred, trusted provider of AI tools. We have trimmed our holding several times in the past 18 months and used the recent strong run to take further profits.

Quarterly Update

+ We sold **Sonova** following a 35% rise in its share price. The company is looking to expand into new geographies to boost growth, but this brings with it execution risk and a less certain outlook. We have reallocated capital to other investments where we see stronger growth potential and greater visibility of earnings.

Laggards

– Xylem is a high-quality water technology company that has been largely ignored in today's narrow markets, enabling us to bring it into the fund at a highly attractive valuation earlier in the year. The company offers a vastly cheaper alternative to replacing urban water pipes, and its digital services and outsourced water management generate high margins and recurring revenues. We previously held Xylem and sold on valuation grounds in 2021, since when its valuation has halved and the quality of the business has improved. We have continued to build our position.

– Cadence Design Systems (Cadence) has a strong moat as one of two leading companies providing software to design and test the vast majority of the world's semiconductors. It is extremely well placed to benefit from long-term demand for increasingly varied, complex and bespoke chips. Cadence's products also help customers reduce energy intensity: its Reality Digital Twin platform, for example, can raise datacentre energy efficiency by up to 30%.

– Fabrinet is a leading manufacturer of fibre optics used for high-speed communication. This technology is as important as compute and memory in datacentres, where AI is doubling required interconnection speeds every two years. Datacentres can contain millions of fibre-optic connections, and links between datacentres can span hundreds of kilometres. Fabrinet works with its customers to develop cutting-edge products that can reduce fixed costs and provide a degree of future proofing in this rapidly changing sector. Swings in market focus in the tech sector presented us with an opportunity to top up this quarter.

Transactions

During the quarter we took profits from several technology and healthcare holdings (**Amphenol**, **Keyence Corp**, **Microsoft**, **Amazon**, **TSMC** and **Labcorp**) and used the proceeds to further broaden the fund's growth drivers powered by demographics, essential infrastructure, automation, digitisation and a changing world order. New additions were **Rollins** (pest control) and **AbbVie** (pharmaceuticals; funded by partial sale of **Roche**). We also added to **Verisk Analytics** (insurance data), **Fabrinet** (fibreoptics) and **Intuitive Surgical** (robot-assisted surgery).

Purchases

The pest control market is growing due to regulation, urbanisation and climate change. **Rollins** is one of two large US pest control companies in an otherwise fragmented market, giving it brand recognition, geographic coverage and an ability to invest that smaller players can't match. Pest control spending is largely non-discretionary; this gives Rollins pricing power and has enabled it to deliver more than 20 successive years of sales growth. Short-term weakness in its residential business caused the shares to dip, giving us an entry point into this high-quality compounding business.

We took an initial position in **AbbVie**, a global pharmaceutical company with world-class franchises in immunology, neuroscience and oncology. Ageing populations, the rising prevalence of chronic diseases and increasing use of innovative biologic medicines are powerful growth tailwinds for AbbVie's diverse portfolio of drugs, which are used by 60 million people in 175 countries each year. AbbVie's limited near-term patent expiry risk gives investors significant visibility for the next five years. This addition to the fund diversifies our pharmaceuticals holdings and adds exposure to neuroscience.

Quarterly Update

Sales

Having halved our **Accenture** position earlier this year, we sold the remainder after a 35% bounce in the shares. In an AI-enabled world, the range of possible outcomes for Accenture has broadened and the outlook for the business is less clear.

DSM-Firmenich's food, nutrition and personal care businesses continue to deliver operationally but its core end markets face multiple headwinds from demographic changes, inflation and lower consumer confidence that could prevent the company from delivering consistent, above-inflation returns over the foreseeable future. We exited our position after a 50% rise in the shares since early March.

Non-equity holdings

The portfolio's focus on shorter-dated and index-linked bonds was rewarded this quarter, providing solid diversification for our equity holdings. Inflation and interest rate expectations continue to rise, with rate increases being implemented by the Federal Reserve and the ECB. We have taken the opportunity to buy high-quality bonds that will provide yields to maturity of 4-4.5% over the coming years.

Gold moved higher during the quarter and the fund's holding in **Franco-Nevada**, which gives exposure to gold mine royalties, rose significantly in response to its most recent set of results.

Stewardship

The recent Hugging Face hack by rogue AI agents highlights that strong cybersecurity is now a necessity, not an option. We met with Verisk Analytics – a business built on proprietary data – to learn how they test and challenge their own cyber defences. In addition to using automated testing and commissioning penetration tests against specific products, Verisk also runs internal red team/blue team 'war games' to help improve its detection and response capability.

Taking things a step further, the company commissions external attacks that are close to the real thing – Verisk's internal teams don't know when the attack will come or its objective. Verisk also takes part in an industry-wide 'bug bounty' programme that rewards security researchers for finding vulnerabilities before malicious attackers do.

Any significant findings from tests are reported to Verisk's management and board. Testing defences is one thing; it's just as important that company management know the results and can act on them.

Top 10 Equity Holdings

Holding	% Weight
Mastercard	4.1
Thermo Fisher Scientific	3.9
Marsh & McLennan	3.8
Taiwan Semiconductor Manufacturing Co	3.7
Amphenol	3.4
Amazon	3.3
Alphabet	3.2
Keyence Corp	3.1
Labcorp Holdings	3.1
Microsoft	2.9
Top 10 Equity Total	**34.4**

Important Information

Fund manager	Navera Investment Management Limited
Ongoing charges	0.75%
Inception date	25th January 2019
Fund size	GBP 475.8m
Pricing	Daily
Base currency	GBP
Fund type	UCITS
Structure	SICAV
Domicile	Luxembourg
Tax status	UK Reporting Fund
SFDR classification	Article 8
Custodian bank	Pictet & Cie (Europe) SA
Dividend paid	January / July
Previous dividend rate (January 2026 / July 2026)	GBP 0.72 / 1.06
ISIN (Dis / Acc)	LU1901197852 / LU1901191145

Navera Investment Management Limited

Riverside House, 2a Southwark Bridge Road, London, SE1 9HA

Switchboard: + 44 20 3740 8350

Authorised and regulated by the Financial Conduct Authority

Registered in England & Wales. Reg. No: 12516583

www.naverainvestment.com

Navera Investment Management Limited is authorised and regulated by the Financial Conduct Authority in the conduct of its investment business. It is registered under number 923827. For more information click on www.fca.org.uk. Navera Investment Management Limited is a discretionary investment manager and does not offer investment advice; and no information contained within this document should be construed as such. If you are in doubt, you should seek advice from a financial adviser.

Disclosure

Investors should consult the KIID and fund prospectus before making any purchase. They can be downloaded from www.naverainvestment.com/fund-library/.

Past performance should not be seen as an indication of future performance.

The value of investments and the income from them may fluctuate and are not guaranteed. Investors may not get back the whole amount they have invested.

Changes in rates of exchange between currencies may cause the value of investments to diminish or to increase.

The views expressed are Navera's own and do not constitute investment advice. Reliance should not be placed on the views and information in this document when taking individual investment and/or strategic decisions. Opinions, estimates, forecasts, projections and statements of financial market trends are based on market conditions at the date of the publication, constitute our judgment and are subject to change without notice. There can be no guarantee they will be met. This is a marketing communication according to ESMA guidelines. For more information please refer to our fund library on our website.

The Protea Fund - Navera High Equity Strategy GBP does not have a sustainability investment objective.

Sources

MSCI: The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). © LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. “FTSE®” is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company’s express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.

Morningstar®. All rights reserved. The information contained herein: 1) is proprietary to Morningstar and/ or its content providers; 2) may not be copied or attributed; and 3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

This fund and FundPartner Solutions (Europe) S.A are authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF).